Biotech Companies Boost Profit on Lower R&D Spending
Bloomberg reported that biotechnology companies around the world have boosted profit by 37% to $5.2B last year partly by cutting spending on research and development, according to Ernst & Young. As...
View ArticleTauriga Sciences Appoints Robert Millman JD to Business Advisory Board
Tauriga Sciences Inc. (OTCQB:TAUG) a diversified life sciences company which currently holds a pending acquisition in the cannabis space, has appointed Robert Millman, JD to its business advisory...
View ArticleClik here to view.
Nasdaq Biotechnology Index Falls
U.S. stocks were down today, with biotechnology companies extending the previous week’s selloff. According to Bloomberg: The Nasdaq Biotechnology Index sank 4.5 percent after its worst week since 2011....
View ArticleClik here to view.
Trans-Pacific Partnership Could Further Depress Biotech Stocks
Up until recently biotech was on a hot streak, with numerous IPOs illustrating investors’ eagerness to support biotechnology companies from their earliest, riskiest stages. However, it seems as though...
View ArticleClik here to view.
Life Sciences: An Investment Thesis
Within the universe of investment options available to those trying to grow their hard-earned cash, there is perhaps no more compelling investment thesis than the science of life. Life sciences is a...
View ArticlePosition Yourself for Big Returns in the Stem Cell Space: Jason Kolbert
Source: George S. Mack of The Life Sciences Report (5/10/13) Stem cell companies have languished long enough in micro-cap territory. The industry is now approaching highly visible phase 2 and phase 3...
View ArticleTwo Companies Follow Unmet Needs to Biotech Profits: Echo He
Source: George S. Mack of The Life Sciences Report (1/30/14) Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients...
View ArticleClik here to view.
Avalanche Biotechnologies Names Paul B. CLeaveland New CEO
Avalanche Biotechnologies (NASDAQ:AAVL) has announced that Paul B. Cleveland will be assuming the appointment of CEO and joining the Board of Directors on December 9. According to the press release: He...
View ArticleClik here to view.
Aimmune Therapeutics Names New Chief Operating Officer
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has named Jeffrey H. Knapp the company’s new Chief Operating Officer. According to the press release: Mr. Knapp brings a nearly 30-year track record of...
View ArticleClik here to view.
New Appointments to iCo Therapeutics’ Board of Directors
iCo Therapeutics Inc. (CVE:ICO) has appointed two new people to its board of directors. Susan Koppy and John Meekison both come to the positions with extensive experience. According to the press...
View ArticleValeant Pharmaceuticals Adds Three New Independent Directors To Its Board
Valeant Pharmaceuticals International, Inc. (NYSE:VRX, TSX:VRX) announced that Dr. Fred Eshelman, Mr. Stephen Fraidin and Mr. Thomas W. Ross, Sr. have joined its Board of Directors as independent...
View ArticleClik here to view.
Immuno-oncology: An Evolving Approach to Cancer Care
Cancer is not just one disease. In fact, there are many types of cancer that all behave differently and can manifest in different parts of the body. Some cancers grow and spread fast while others...
View Article10 Top Generic Pharmaceutical Companies
Did you know that the generics market is currently the highest earning sector in the India’s pharmaceutical market, with 70 percent of market share by revenue? Further to that, the country’s generic...
View ArticleClik here to view.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) will present new data demonstrating the breadth and diversity of its marketed and pipeline multiple sclerosis (MS) therapies at the 68th annual...
View ArticleClik here to view.
Top 5 Holdings in PowerShares Dynamic Biotechnology & Genome ETF
Investors looking for a small cap biotechnology ETF might be out of luck, as no ETF in the biotech sector is specifically designed to target only small cap companies. However, one ETF that has been...
View ArticleClik here to view.
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™...
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
View ArticleClik here to view.
Aimmune Therapeutics Names New Chief Operating Officer
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has named Jeffrey H. Knapp the company’s new Chief Operating Officer. According to the press release: Mr. Knapp brings a nearly 30-year track record of...
View ArticleGenmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
Company Announcement Oral plenary session presentation on daratumumab Phase III Castor study data Trial in progress poster presentation from Phase I study of subcutaneous daratumumab Copenhagen,...
View ArticleClik here to view.
LakePharma to Showcase Antibody Discovery and Protein Engineering Expertise...
BELMONT, Calif.–(BUSINESS WIRE)–LakePharma, Inc. the leading protein engineering CRO dedicated to providing integrated biologics discovery and development services, will present key data at the...
View ArticleRepligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes...
WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal...
View Article
